Bayer: Nexavar Lung Cancer Phase III Study Misses Primary Endpoint - NASDAQ

FRANKFURT -(Dow Jones)- German chemical and pharmaceutical group Bayer AG (BAYN.XE) and Onyx Pharmaceuticals, Inc. (ONXX) Tuesday said a phase III trial of Nexavar treatment for lung cancer patients failed to meet its primary endpoint of ...

Onyx/Bayer's Nexavar Disappoints - Yahoo Finance

Bayer AG (BAYRY.PK) recently announced that a phase III trial of Nexavar (sorafenib), co-developed and marketed with Onyx Pharmaceuticals Inc. (ONXX), failed to meet the primary endpoint. The MISSION (Monotherapy administration of Sorafenib in ...

Phase 3 MISSION trial of Nexavar (sorafenib) in Patients with Non-Small Cell Lung Cancer Did Not Meet Primary Endpoint of Improving Overall Survival - Yahoo Finance

WAYNE, N.J. and SOUTH SAN FRANCISCO, Calif., May 22, 2012 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. (ONXX) today announced that a Phase 3 trial evaluating Nexavar ® (sorafenib) tablets in patients with ...

Generics Drive Down Drug Prices In India, TPP Trying To Stop That - Tech Dirt

Back in March, we wrote about an important development in India, where a compulsory license for Bayer's Nexavar anti-cancer drug was granted. Bayer, of course, is fighting back: in its 37-page appeal to the Intellectual Property Appellate Board ...

Aveo kidney cancer drug more tolerated than Nexavar - msnbc.com

(Reuters) - Patients taking a kidney cancer drug being developed by Aveo Pharmaceuticals Inc were half as likely to need a break from the medication due to side effects than those on the widely used medicine Nexavar, according to data released ...

Bayer to Present Data on Late-Stage Oncology Compounds at ASCO 2012 - Phramalive.com

About Nexavar Nexavar is approved in the U.S. for the treatment of patients with unresectable liver cancer and for the treatment of patients with advanced kidney cancer. Nexavar inhibits both the tumor cell and tumor vasculature. In preclinical studies ...

Bayer challenges Nexavar generic license order in India - in.news.yahoo.com

(Reuters) - Drugmaker Bayer said on Saturday it had challenged an Indian patents office order that allowed domestic rival Natco Pharma to sell a cheap generic version of the German firm's liver and kidney cancer drug Nexavar in India. In March, the patents ...

Natco’s compulsory licence has had the intended effect - Daily News and Analysis

The message in the compulsory licence granted to Natco Pharma to sell a generic version of patented cancer drug Nexavar appears to have hit home. Earlier this month, Cipla, which was already selling generic Nexavar at Rs28,000 for a month’s ...

48th Annual Meeting of the American Society of Clinical Oncology (ASCO): Bayer to Present Data on Late-Stage Oncology Compounds at ASCO 2012 - Phramalive.com

About Nexavar Nexavar is approved in the U.S. for the treatment of patients with unresectable liver cancer and for the treatment of patients with advanced kidney cancer. Nexavar inhibits both the tumor cell and tumor vasculature. In preclinical studies ...

Pfizer’s Torisel Misses Endpoints in Renal Cell Carcinoma Trial Testing Second-Line Setting - Genetic Engineering News

The trial compared Torisel and Nexavar in patients whose disease had progressed on or after treatment with the company’s approved drug Sutent. Although PFS was numerically higher in patients treated with Torisel, the difference was not ...